In a major breakthrough, the World Health Organization (WHO) has updated its 2025 guidelines to recommend lenacapavir, a long-acting injectable drug for HIV prevention, especially in high-risk populations and regions with high infection rates. The announcement came at the 13th International AIDS Society Conference in Kigali, Rwanda.
What is Lenacapavir?
Developed by Gilead Sciences in New Delhi, lenacapavir is a twice-yearly injection that blocks HIV replication at multiple stages. It offers a more convenient and effective alternative to daily oral PrEP pills, especially for individuals facing healthcare access issues or stigma.
Target Groups & Benefits
The drug is aimed at vulnerable groups including sex workers, transgender people, MSM, prisoners, and adolescents. Its long-acting nature ensures better compliance and improved protection.
Access & Cost
Thanks to a partnership with the Global Fund, lenacapavir will be provided at cost price in low- and middle-income countries. However, in the U.S., it is priced at around $28,000 annually.
Challenges
Despite this advancement, global HIV prevention efforts face funding cuts, potentially undermining progress in several countries. WHO stresses the need for sustained support and wider access to prevention tools.
Lenacapavir marks a significant step in transforming HIV prevention, offering hope for reducing new infections worldwide.
